China's Shanghai Fosun joins race to buy India injectables maker Gland

China flag
China flag

China's Shanghai Fosun Pharmaceuticals said it is in the race to buy unlisted Hyderabad-based injectables maker Gland Pharma, joining Baxter International and buyout firm Advent International, for a company valued at around $1.5 billion.

In a notice to the Hong Kong Stock Exchange, Shanghai Fosun said its interest so far was non-binding and was made known through a unit of the Fosun conglomerate, Fosun Industrial.

Gland is backed by leveraged buyout firm KKR & Co., which along with the firm's founders hold around 96% of the company, according to reported figures. For Shanghai Fosun, the purchase would open a pathway into the valuable sales and manufacturing of sterile injectable medicines now dominated by Pfizer ($PFE) following its recent Hospira purchase.

Whitepaper

Simplify and Accelerate Drug R&D With the MarkLogic Data Hub Service for Pharma R&D

Researchers are often unable to access the information they need. And, even when data does get consolidated, researchers find it difficult to sift through it all and make sense of it in order to confidently draw the right conclusions and share the right results. Discover how to quickly and easily find, synthesize, and share information—accelerating and improving R&D.

Also in the fray, Reuters reported in April, is Ahmedabad-based Torrent Pharmaceuticals, which hails from the manufacturing hub of Gujarat.

KKR's 2013 original investment was about $200 million, according to Reuters, the largest ever private equity amount in the India drug industry at the time and that valued the company around $600 million.

Injectables in India have drawn attention in the past few years as firms like Jordan-based Hikma faced manufacturing quality issues with U.S-based operations in the space, and Mylan ($MYL) snapped up Indian injectables maker Strides Arcolab for $1.75 billion, which closed in 2014 and is now called Strides Shasun.

- here's the release
- here's a story in Livemint

Suggested Articles

Astellas buys gene therapy player Audentes for $3 billion. Keytruda and Opdivo fail to win coverage in China. Hanmi inks I-O deal with Rapt.

It’s a familiar scene in the race onto China’s national reimbursement list: Drugmakers cut prices by an average 60.7% to win coverage.

After a longer follow-up of 25 months, Alunbrig cut the risk of disease progression by 51% compared with Xalkori in ALK inhibitor-naïve NSCLC.